• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

葡萄膜黑色素瘤的免疫基础:免疫治疗是否有理论依据?

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

作者信息

Rossi Ernesto, Schinzari Giovanni, Zizzari Ilaria Grazia, Maiorano Brigida Anna, Pagliara Monica Maria, Sammarco Maria Grazia, Fiorentino Vincenzo, Petrone Gianluigi, Cassano Alessandra, Rindi Guido, Bria Emilio, Blasi Maria Antonietta, Nuti Marianna, Tortora Giampaolo

机构信息

Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, 00168 Rome, Italy.

Medical Oncology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

出版信息

Cancers (Basel). 2019 Jul 26;11(8):1055. doi: 10.3390/cancers11081055.

DOI:10.3390/cancers11081055
PMID:31357439
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6721347/
Abstract

No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.

摘要

目前尚未确立转移性葡萄膜黑色素瘤(mUM)的标准治疗方法。尽管葡萄膜黑色素瘤尚未纳入使用检查点抑制剂的III期临床试验,但免疫疗法仍是该疾病的常用治疗方法。不幸的是,只有少数患者通过免疫疗法获得临床益处。为了解免疫疗法是否仍能在该疾病中发挥作用,对mUM的免疫特征进行了综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4b/6721347/485b04fa244e/cancers-11-01055-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4b/6721347/485b04fa244e/cancers-11-01055-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4b/6721347/485b04fa244e/cancers-11-01055-g001.jpg

相似文献

1
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?葡萄膜黑色素瘤的免疫基础:免疫治疗是否有理论依据?
Cancers (Basel). 2019 Jul 26;11(8):1055. doi: 10.3390/cancers11081055.
2
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.程序性细胞死亡蛋白1或联合程序性死亡蛋白1/细胞毒性T淋巴细胞相关抗原4抑制治疗转移性葡萄膜黑色素瘤的预后因素及结局
Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.
3
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.转移性葡萄膜黑色素瘤在单独接受抗 PD-1 治疗后进展,随后接受抗 CTLA-4 和抗 PD-1 联合治疗,获得持久缓解。
J Immunother Cancer. 2018 Feb 12;6(1):13. doi: 10.1186/s40425-018-0322-1.
4
Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.免疫检查点抑制剂和新型免疫疗法在葡萄膜黑色素瘤中的作用。
Chin Clin Oncol. 2018 Feb;7(1):8. doi: 10.21037/cco.2018.01.05.
5
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.葡萄膜黑色素瘤治疗的免疫疗法:现状与新兴疗法
Curr Oncol Rep. 2017 Jul;19(7):45. doi: 10.1007/s11912-017-0606-5.
6
Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review.转移性葡萄膜黑色素瘤的放射治疗与全身免疫治疗:一项临床回顾性研究
Front Oncol. 2024 Jul 4;14:1406872. doi: 10.3389/fonc.2024.1406872. eCollection 2024.
7
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂:黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
8
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.不可切除或转移性葡萄膜黑色素瘤的免疫检查点阻断治疗:系统评价。
Cancer Treat Rev. 2017 Nov;60:44-52. doi: 10.1016/j.ctrv.2017.08.009. Epub 2017 Aug 24.
9
A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.转移性葡萄膜黑色素瘤伴自身免疫时对伊匹单抗和纳武单抗有显著应答。
Pigment Cell Melanoma Res. 2017 Jan;30(6):558-562. doi: 10.1111/pcmr.12607. Epub 2017 Jul 23.
10
Pembrolizumab as first-line treatment for metastatic uveal melanoma.派姆单抗作为一线治疗转移性葡萄膜黑色素瘤的药物。
Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185. doi: 10.1007/s00262-019-02352-6. Epub 2019 Jun 7.

引用本文的文献

1
Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort study.肿瘤坏死因子α(TNF)抑制剂免疫抑制治疗后新发恶性肿瘤的长期风险:一项多中心回顾性队列研究。
J Inflamm (Lond). 2025 Aug 14;22(1):34. doi: 10.1186/s12950-025-00445-x.
2
Malignant melanoma complicated with cataract and secondary glaucoma: A case report.恶性黑色素瘤合并白内障及继发性青光眼:病例报告
Oncol Lett. 2024 Aug 30;28(5):520. doi: 10.3892/ol.2024.14653. eCollection 2024 Nov.
3
Identification of feature genes and molecular mechanisms involved in cell communication in uveal melanoma through analysis of single‑cell sequencing data.

本文引用的文献

1
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.依匹单抗联合帕博利珠单抗对比安慰剂联合帕博利珠单抗用于不可切除或转移性黑色素瘤患者(ECHO-301/KEYNOTE-252):一项 III 期、随机、双盲研究。
Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.
2
Pembrolizumab as first-line treatment for metastatic uveal melanoma.派姆单抗作为一线治疗转移性葡萄膜黑色素瘤的药物。
Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185. doi: 10.1007/s00262-019-02352-6. Epub 2019 Jun 7.
3
通过单细胞测序数据分析鉴定葡萄膜黑色素瘤细胞通讯中涉及的特征基因和分子机制。
Oncol Lett. 2024 Aug 20;28(5):503. doi: 10.3892/ol.2024.14636. eCollection 2024 Nov.
4
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.葡萄膜黑色素瘤中具有转移特性的肿瘤免疫杂交细胞的检测
Biomark Res. 2024 Jul 20;12(1):67. doi: 10.1186/s40364-024-00609-6.
5
The multiple roles of autophagy in uveal melanoma and the microenvironment.自噬在葡萄膜黑色素瘤和微环境中的多重作用。
J Cancer Res Clin Oncol. 2024 Mar 11;150(3):121. doi: 10.1007/s00432-023-05576-3.
6
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.从分子生物学到葡萄膜黑色素瘤的新型免疫疗法和纳米医学。
Curr Oncol. 2024 Feb 1;31(2):778-800. doi: 10.3390/curroncol31020058.
7
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.在葡萄膜黑色素瘤中检测具有转移特性的肿瘤免疫杂交细胞。
Res Sq. 2023 Dec 6:rs.3.rs-3694879. doi: 10.21203/rs.3.rs-3694879/v1.
8
Identification of co-expressed gene networks promoting CD8 T cell infiltration and having prognostic value in uveal melanoma.鉴定促进 CD8 T 细胞浸润并具有葡萄膜黑色素瘤预后价值的共表达基因网络。
BMC Ophthalmol. 2023 Aug 10;23(1):354. doi: 10.1186/s12886-023-03098-7.
9
Cross talk between tumor stemness and microenvironment for prognosis and immunotherapy of uveal melanoma.肿瘤干性与微环境的串扰对葡萄膜黑色素瘤预后和免疫治疗的影响。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11951-11968. doi: 10.1007/s00432-023-05061-x. Epub 2023 Jul 7.
10
FGF-trapping hampers cancer stem-like cells in uveal melanoma.成纤维细胞生长因子捕获可抑制葡萄膜黑色素瘤中的癌症干细胞样细胞。
Cancer Cell Int. 2023 May 11;23(1):89. doi: 10.1186/s12935-023-02903-z.
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
携带死肿瘤抗原的天然小鼠常规型 1 树突状细胞的有效癌症免疫疗法。
J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5.
4
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.免疫疗法对转移性黏膜或葡萄膜黑色素瘤患者的疗效。
J Oncol. 2018 Dec 2;2018:1908065. doi: 10.1155/2018/1908065. eCollection 2018.
5
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.眼葡萄膜黑色素瘤患者对抗 PD-1 治疗的罕见反应揭示了高突变肿瘤中的种系 MBD4 突变。
Nat Commun. 2018 May 14;9(1):1866. doi: 10.1038/s41467-018-04322-5.
6
Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.肿瘤细胞和免疫细胞程序性死亡配体 1 的表达与葡萄膜黑色素瘤患者更好的预后相关,并与肿瘤浸润淋巴细胞减少相关。
Mod Pathol. 2018 Aug;31(8):1201-1210. doi: 10.1038/s41379-018-0043-5. Epub 2018 Mar 26.
7
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).西罗莫司联合达卡巴嗪治疗转移性葡萄膜黑色素瘤患者的 III 期、多中心、随机试验(SUMIT)。
J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12.
8
Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.免疫检查点抑制剂和新型免疫疗法在葡萄膜黑色素瘤中的作用。
Chin Clin Oncol. 2018 Feb;7(1):8. doi: 10.21037/cco.2018.01.05.
9
Cellular and Molecular Mechanisms of Anterior Chamber-Associated Immune Deviation (ACAID): What We Have Learned from Knockout Mice.前房相关免疫偏离(ACAID)的细胞和分子机制:我们从基因敲除小鼠中学到了什么。
Front Immunol. 2017 Nov 30;8:1686. doi: 10.3389/fimmu.2017.01686. eCollection 2017.
10
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.葡萄膜黑色素瘤和皮肤黑色素瘤在肿瘤转移中的程序性死亡受体配体1(PD-L1)表达情况有所不同。
Immunotherapy. 2017 Dec;9(16):1323-1330. doi: 10.2217/imt-2017-0066.